Literature DB >> 18178844

The NF-kappaB canonical pathway is involved in the control of the exonucleolytic processing of coding ends during V(D)J recombination.

M Margarida Souto-Carneiro1, Ruth Fritsch, Nuno Sepúlveda, M João Lagareiro, Nuno Morgado, Nancy S Longo, Peter E Lipsky.   

Abstract

V(D)J recombination is essential to produce an Ig repertoire with a large range of Ag specificities. Although NF-kappaB-binding sites are present in the human and mouse IgH, Igkappa, and Iglambda enhancer modules and RAG expression is controlled by NF-kappaB, it is not known whether NF-kappaB regulates V(D)J recombination mechanisms after RAG-mediated dsDNA breaks. To clarify the involvement of NF-kappaB in human V(D)J recombination, we amplified Ig gene rearrangements from individual peripheral B cells of patients with X-linked anhidrotic ectodermal dysplasia with hyper-IgM syndrome (HED-ID) who have deficient expression of the NF-kappaB essential modulator (NEMO/Ikkgamma). The amplification of nonproductive Ig gene rearrangements from HED-ID B cells reflects the influence of the Ikkgamma-mediated canonical NF-kappaB pathway on specific molecular mechanisms involved in V(D)J recombination. We found that the CDR3(H) from HED-ID B cells were abnormally long, as a result of a marked reduction in the exonuclease activity on the V, D, and J germline coding ends, whereas random N-nucleotide addition and palindromic overhangs (P nucleotides) were comparable to controls. This suggests that an intact canonical NF-kappaB pathway is essential for normal exonucleolytic activity during human V(D)J recombination, whereas terminal deoxynucleotide transferase, Artemis, and DNA-dependent protein kinase catalytic subunit activity are not affected. The generation of memory B cells and somatic hypermutation were markedly deficient confirming a role for NF-kappaB in these events of B cell maturation. However, selection of the primary B cell repertoire appeared to be intact and was partially able to correct the defects generated by abnormal V(D)J recombination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178844     DOI: 10.4049/jimmunol.180.2.1040

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Decreased expression in nuclear factor-κB essential modulator due to a novel splice-site mutation causes X-linked ectodermal dysplasia with immunodeficiency.

Authors:  Shuhei Karakawa; Satoshi Okada; Miyuki Tsumura; Yoko Mizoguchi; Norioki Ohno; Shin'ichiro Yasunaga; Motoaki Ohtsubo; Tomoki Kawai; Ryuta Nishikomori; Takemasa Sakaguchi; Yoshihiro Takihara; Masao Kobayashi
Journal:  J Clin Immunol       Date:  2011-07-01       Impact factor: 8.317

2.  NF-κB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes.

Authors:  Meta Volcic; Sabine Karl; Bernd Baumann; Daniela Salles; Peter Daniel; Simone Fulda; Lisa Wiesmüller
Journal:  Nucleic Acids Res       Date:  2011-09-09       Impact factor: 16.971

3.  V(D)J recombination process and the Pre-B to immature B-cells transition are altered in Fanca-/- mice.

Authors:  Thuy Vy Nguyen; Patrycja Pawlikowska; Virginie Firlej; Filippo Rosselli; Saïd Aoufouchi
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

4.  The Role of the Nuclear Factor κB Pathway in the Cellular Response to Low and High Linear Energy Transfer Radiation.

Authors:  Christine E Hellweg; Luis F Spitta; Kristina Koch; Arif A Chishti; Bernd Henschenmacher; Sebastian Diegeler; Bikash Konda; Sebastian Feles; Claudia Schmitz; Thomas Berger; Christa Baumstark-Khan
Journal:  Int J Mol Sci       Date:  2018-07-30       Impact factor: 5.923

5.  Recovering probabilities for nucleotide trimming processes for T cell receptor TRA and TRG V-J junctions analyzed with IMGT tools.

Authors:  Kevin Bleakley; Marie-Paule Lefranc; Gérard Biau
Journal:  BMC Bioinformatics       Date:  2008-10-02       Impact factor: 3.169

Review 6.  Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study.

Authors:  Hui Yu; Liangbin Lin; Zhiqiang Zhang; Huiyuan Zhang; Hongbo Hu
Journal:  Signal Transduct Target Ther       Date:  2020-09-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.